FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011643412> ?p ?o ?g. }

• W3011643412 abstract "Abstract We tested two metabotropic glutamate receptor 2/3 (mGluR2/3) agonist prodrugs – pomaglumetad (POMA) and TS-134 – including a high-dose of POMA that was four times the dose tested in the failed phase schizophrenia III trials – in two proof of mechanism, Phase Ib studies using identical pharmacoBOLD target-engagement methodology. The POMA study was a double-blind, NIMH-sponsored, 10-day study of 80 or 320 mg/d POMA or placebo (1:1:1 ratio), designed to detect d>0.8 sd between-group effect-size differences. The TS-134 study was a single-blind, industry-sponsored, 6-day study of 20 or 60 mg/d TS-134 or placebo (5:5:2 ratio), designed to permit effect-size estimation for future studies. Primary outcomes were ketamine-induced changes in pharmacoBOLD in the dorsal anterior cingulate cortex (dACC) and Brief Psychiatric Rating Scale (BPRS). 95 healthy controls were randomized to POMA and 63 to TS-134. High-dose POMA had significant within and between-group reduction in ketamine-induced BPRS total symptoms (p<0.01, d=-0.41; p=0.04, d=-0.44, respectively) but neither POMA dose significantly suppressed ketamine-induced dACC pharmacoBOLD. In contrast, low-dose TS-134 had significant/trend level, moderate to large within and between group effects on BPRS positive symptoms (p=0.02, d=-0.36; p=0.008, d=-0.82, respectively) and dACC pharmacoBOLD (p=0.004, d=-0.56; p=0.079, d=-0.50, respectively) using pooled across-study placebo data. High-dose POMA exerted significant effects on clinical symptoms, but not on target engagement, suggesting a higher dose may yet be needed. TS-134 20 mg showed evidence of symptom reduction and target engagement, indicating a curvilinear dose-response curve. These results warrant further investigation of mGluR2/3 and other glutamate-targeted treatments for schizophrenia." @default.
• W3011643412 created "2020-03-23" @default.
• W3011643412 creator A5003154905 @default.
• W3011643412 creator A5006873713 @default.
• W3011643412 creator A5008479872 @default.
• W3011643412 creator A5034093325 @default.
• W3011643412 creator A5040680099 @default.
• W3011643412 creator A5045818277 @default.
• W3011643412 creator A5055811550 @default.
• W3011643412 creator A5058205666 @default.
• W3011643412 creator A5066820418 @default.
• W3011643412 creator A5069167318 @default.
• W3011643412 creator A5070720166 @default.
• W3011643412 creator A5071039477 @default.
• W3011643412 creator A5072574087 @default.
• W3011643412 creator A5074474145 @default.
• W3011643412 creator A5075093461 @default.
• W3011643412 creator A5086344811 @default.
• W3011643412 creator A5088564036 @default.
• W3011643412 creator A5088797464 @default.
• W3011643412 date "2020-03-12" @default.
• W3011643412 modified "2023-10-16" @default.
• W3011643412 title "Clinical Efficacy and Target Engagement of Glutamatergic Drugs: Placebo-Controlled RCTs of Pomaglumetad and TS-134 for Reversal of Ketamine-Induced Psychotic Symptoms and PharmacoBOLD in Healthy Volunteers" @default.
• W3011643412 cites W1914381346 @default.
• W3011643412 cites W1971460793 @default.
• W3011643412 cites W1977139958 @default.
• W3011643412 cites W1984141645 @default.
• W3011643412 cites W1989025308 @default.
• W3011643412 cites W1991288075 @default.
• W3011643412 cites W1991362566 @default.
• W3011643412 cites W1997751011 @default.
• W3011643412 cites W2001063043 @default.
• W3011643412 cites W2008908272 @default.
• W3011643412 cites W2017259777 @default.
• W3011643412 cites W2019358247 @default.
• W3011643412 cites W2020333990 @default.
• W3011643412 cites W2020844317 @default.
• W3011643412 cites W2023986042 @default.
• W3011643412 cites W2026653320 @default.
• W3011643412 cites W2027817574 @default.
• W3011643412 cites W2027858713 @default.
• W3011643412 cites W2028884770 @default.
• W3011643412 cites W2035611331 @default.
• W3011643412 cites W2038615690 @default.
• W3011643412 cites W2043532758 @default.
• W3011643412 cites W2049139447 @default.
• W3011643412 cites W2055297542 @default.
• W3011643412 cites W2055518130 @default.
• W3011643412 cites W2056603806 @default.
• W3011643412 cites W2061506085 @default.
• W3011643412 cites W2062657302 @default.
• W3011643412 cites W2068256291 @default.
• W3011643412 cites W2069849124 @default.
• W3011643412 cites W2087728812 @default.
• W3011643412 cites W2089126361 @default.
• W3011643412 cites W2090969443 @default.
• W3011643412 cites W2103784702 @default.
• W3011643412 cites W2103903531 @default.
• W3011643412 cites W2113113845 @default.
• W3011643412 cites W2119151345 @default.
• W3011643412 cites W2140506009 @default.
• W3011643412 cites W2144463664 @default.
• W3011643412 cites W2147937603 @default.
• W3011643412 cites W2158137297 @default.
• W3011643412 cites W2159039084 @default.
• W3011643412 cites W2159155203 @default.
• W3011643412 cites W2259684659 @default.
• W3011643412 cites W2312770619 @default.
• W3011643412 cites W2327693359 @default.
• W3011643412 cites W2475864443 @default.
• W3011643412 cites W2606941164 @default.
• W3011643412 cites W2607182730 @default.
• W3011643412 cites W2623131989 @default.
• W3011643412 cites W2732930884 @default.
• W3011643412 cites W2758640643 @default.
• W3011643412 cites W2768811819 @default.
• W3011643412 cites W2770367203 @default.
• W3011643412 cites W2783894827 @default.
• W3011643412 cites W2791092622 @default.
• W3011643412 cites W2791444586 @default.
• W3011643412 cites W2884510193 @default.
• W3011643412 cites W2891810482 @default.
• W3011643412 cites W2893587285 @default.
• W3011643412 cites W2913142180 @default.
• W3011643412 cites W2914698032 @default.
• W3011643412 cites W2957311488 @default.
• W3011643412 cites W4322703206 @default.
• W3011643412 doi "https://doi.org/10.1101/2020.03.09.20029827" @default.
• W3011643412 hasPublicationYear "2020" @default.
• W3011643412 type Work @default.
• W3011643412 sameAs 3011643412 @default.
• W3011643412 citedByCount "3" @default.
• W3011643412 countsByYear W30116434122020 @default.
• W3011643412 countsByYear W30116434122021 @default.
• W3011643412 crossrefType "posted-content" @default.
• W3011643412 hasAuthorship W3011643412A5003154905 @default.
• W3011643412 hasAuthorship W3011643412A5006873713 @default.
• W3011643412 hasAuthorship W3011643412A5008479872 @default.
• W3011643412 hasAuthorship W3011643412A5034093325 @default.
• W3011643412 hasAuthorship W3011643412A5040680099 @default.

• next